Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAK 012

Next Previous
X
Search
Drug Profile

TAK 012

Alternative Names: Allogeneic variable delta 1 gamma-delta T cell cancer therapy - Takeda; GDX-012; TAK-012

Latest Information Update: 21 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GammaDelta Therapeutics
  • Developer Takeda
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 11 Jul 2023 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT05886491)
  • 07 Jun 2023 Takeda plans a phase I/IIa trial for Acute Myeloid Leukemia (AML) (Second-line therapy or greater) in USA (IV) in July 2023 (NCT05886491)
  • 20 Jul 2022 GammaDelta Therapeutics terminates a phase I trial for Acute myeloid leukaemia in USA (IV) due to strategic reasons (NCT05001451)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top